Cookie preferences
We use essential cookies for sign-in and security. With your permission, we also use Plausible Analytics to understand how the site is used. See our Privacy Policy
T1D Fund is the world's first scaled venture fund dedicated exclusively to type 1 diabetes, operating as an impact investment fund that supports promising companies through equity investments and expertise. They focus specifically on accelerating treatments, prevention, and cures for the approximately 9 million people living with T1D globally.
The fund operates as a powerful platform for collaboration, using catalytic capital and expertise to de-risk investments and create a flywheel effect that attracts other investors to the T1D space. As a wholly owned, not-for-profit independently run subsidiary of Breakthrough T1D, they leverage their intellectual capital and expert network to offer comprehensive support to portfolio companies, steering them through regulatory, clinical, and commercial milestones.
With over $200 million in assets under management and 25+ active portfolio companies, T1D Fund creates significant impact in the diabetes ecosystem by reinvesting 100% of returns to propel continuous progress. Their unique position as subject matter experts combined with access to Breakthrough T1D's extensive network of research, clinical, and medical expertise enables them to transform the landscape of T1D investment and accelerate the development of life-changing therapies.
T1D Fund strategically invests in companies developing disease-modifying therapies and cures for type 1 diabetes, focusing on supporting innovators through equity investments combined with strategic expertise. They operate by de-risking programs and propelling innovation specifically within the T1D space, acting as critical thought partners to their portfolio companies.
The fund creates a continuous cycle of progress by reinvesting all returns back into foundational research and program development acceleration. Their approach combines scientific expertise, deep industry experience, and access to the extensive network and resources of Breakthrough T1D and The Leona M. and Harry B. Helmsley Charitable Trust to maximize impact for the T1D community.
Photo credit: T1D Fund
Dedicated T1D Expertise
Access to specialized knowledge and network focused exclusively on type 1 diabetes innovation and development.
Breakthrough T1D Network
Portfolio companies gain access to extensive research, clinical, and medical expertise through parent organization.
Continuous Reinvestment
100% of fund returns are reinvested to create ongoing cycles of progress and sustained funding.
De-risking Support
Strategic guidance through regulatory, clinical, and commercial milestones using deep industry experience.
Sectors
Focus areas
Locations
